Zevra Therapeutics: Strong Financials, Strategic FDA Approval, and Growth Prospects Drive Buy Rating
Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Zevra Therapeutics (ZVRA – Research Report). The associated ...
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease
Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a ...
Precigen’s Strategic Advancements and FDA Alignment Bolster Buy Rating
Analyst Jason Butler of JMP Securities reiterated a Buy rating on Precigen (PGEN – Research Report), with a price target of $7.00. Jason ...